Cross-Cutting Mechanisms
Several mechanisms span multiple steps of the energy chain and cannot be localized to any single step. They are collected here to preserve the parallel structure of the ten-step analysis while retaining the full mechanistic content.
1 Calcium Dysregulation and the Na+/K+-ATPase Failure Cascade
Mitochondria buffer cytosolic calcium and use it for signaling:
- Calcium overload: Excessive mitochondrial calcium triggers permeability transition
- ER-mitochondria crosstalk: Abnormal calcium transfer between organelles
- Apoptosis signaling: Calcium overload can trigger cell death pathways
- Enzyme regulation: Many mitochondrial enzymes are calcium-sensitive
1.1 The Na+/K+-ATPase Failure Cascade
The sodium-potassium pump (Na+/K+-ATPase) normally maintains a steep electrochemical gradient: 3~Na+ exported for every 2~K+ imported per cycle. This gradient is essential for nerve signaling, glucose transport, cell volume regulation, and muscle contraction. In ME/CFS, multiple mechanisms converge to slow this pump:
- Hypoperfusion: Reduced oxygen and substrate delivery impairs the ATP supply the pump requires (each cycle consumes one ATP molecule).
- Frequent anaerobic threshold crossing: Anaerobic metabolism produces lactate, lowering intracellular pH and activating the sodium-hydrogen exchanger (NHE1), which imports Na+ to extrude H+; the already-impaired pump cannot clear this excess Na+.
- \(\beta_2\)-adrenergic receptor dysfunction: These receptors directly activate Na+/K+-ATPase during physical activity; their desensitization and autoantibody blocking (see Section blood volume of Chapter Cardiovascular Dysfunction) removes this activation signal.
When intracellular Na+ rises sufficiently, the sodium-calcium exchanger (NCX) enters “reverse mode”: instead of exporting Ca2+ (its normal function), it imports Ca2+ in exchange for Na+ efflux. The result is excessive intracellular calcium accumulation—a cytotoxic state.
Wirth and Scheibenbogen (2022) used MRI-based sodium imaging to measure intracellular sodium in the gastrocnemius muscle of ME/CFS patients after a calf-raise protocol (30 per minute for 3~minutes). ME/CFS patients showed a 30% intracellular sodium rise versus 17% in controls, measured 12~minutes post-exercise (likely underestimating the peak difference during exertion) . ME/CFS patients also had elevated muscle sodium at baseline, and higher resting sodium correlated with lower handgrip strength—suggesting pump dysfunction as a primary driver of weakness.
Falsifiability: weakly — Falsified if (a) intracellular calcium levels in ME/CFS muscle fibres are normal during PEM, or (b) calcium channel blockers or NCX inhibitors fail to reduce PEM severity, or (c) an alternative mechanism for exercise-induced muscle necrosis in ME/CFS is identified
The calcium toxicity cascade—Na+/K+-ATPase failure → NCX reversal → Ca2+ overload—may be the primary cellular mechanism of post-exertional malaise. Excessive intracellular calcium causes muscle pain, direct mitochondrial damage, reduced ATP production, and in severe cases drives mitochondria to consume rather than produce ATP in a futile attempt to buffer the calcium load (Walkon, Strubbe-Rivera, and Bazil 2022). At extreme levels, calcium toxicity causes necrotic muscle fibre death.
Appelman et al. (2024) provided direct histological evidence: light microscopy of Long~COVID patient muscle biopsies revealed an unusually high number of necrotic (dead) muscle fibres during PEM (Appelman et al. 2024). Wirth and Scheibenbogen (2024) argue that calcium toxicity is the only mechanism in their systematic analysis that can account for exercise-induced muscle fibre necrosis , though independent systematic reviews of this claim have not yet been published.
Wirth and Scheibenbogen propose positioning ME/CFS as an “acquired ischemic mitochondrial myopathy” — a classification that, if validated, would imply dysfunction in mitochondria occurring simultaneously with reduced blood perfusion (ischemia). PEM severity and duration depend on the extent of calcium overload and the body’s capacity to restore ionic homeostasis—a process severely hampered by the same hypoperfusion that caused the overload.
Testable predictions:
- (a): Intracellular calcium levels (measured by 31P-MRS or calcium-sensitive fluorescent probes in biopsy) are elevated in ME/CFS muscle during PEM compared to baseline.
- (b): The degree of post-exercise sodium accumulation (Wirth-Scheibenbogen sodium MRI protocol) predicts PEM severity and duration in a dose-response relationship.
- (c): Pharmacological Na+/K+-ATPase stimulation (e.g., MDC002/Mitodicure) reduces or eliminates PEM by preventing the sodium-calcium cascade from reaching the toxicity threshold.
Treatment implication: If calcium toxicity is the proximate PEM mechanism, then MDC002—which restores Na+/K+-ATPase function—would address the immediate trigger. Upstream interventions improving muscular blood flow (see bradykinin model, Section blood volume of Chapter Cardiovascular Dysfunction) would reduce the pump’s metabolic burden. Taurine may provide supplementary support at two nodes of this cascade: maintaining Na+/K+-ATPase activity and buffering downstream calcium overload (see Section Amino Acids in Chapter Supplements and Nutraceuticals ); however, no ME/CFS supplementation trial has tested this hypothesis. Certainty: 0.50—strong mechanistic logic supported by the sodium MRI data and muscle necrosis finding, but direct calcium measurements in ME/CFS muscle during PEM have not yet been performed.
Mechanistic scope limitation: The assertion that AIMM is DOWNSTREAM of other mechanisms rather than trigger-capable itself is a hypothesis, not a demonstrated fact. The calcium toxicity cascade (hypoperfusion → Na+/K+-ATPase failure → NCX reversal → Ca2+ overload) could be initiated directly by mitochondrial damage (viral, genetic, environmental) without requiring the four upstream mechanisms classified as trigger-capable in our causal hierarchy. The vascular primacy argument presents correlations as evidence of directionality but does not rule out reverse causality (mitochondrial dysfunction causing vascular pathology through energy-dependent endothelial cell dysfunction). MDC002 addresses the proximate PEM trigger but does not correct the upstream cause that initiated the disease state. Consequently, MDC002 monotherapy is expected to produce partial or temporary benefit in many patients, and no benefit in patients whose ME/CFS is driven primarily by non-AIMM mechanisms (e.g., CNS energy crisis, metabolic safe mode lock, TRPM3 channelopathy without secondary AIMM). The most clinically realistic expectation, consistent with Wirth’s own position that “severely ill patients will need multiple medications,” is that MDC002 will work best as part of combination therapy: downstream ion homeostasis restoration (MDC002) plus upstream mechanism-targeted interventions (autoantibody removal, beta-2 AR resensitization, blood volume restoration). However, this combination requirement is itself speculative and has not been empirically tested. Expected responder phenotype: sodium MRI-confirmed overload, exercise-triggered PEM with delayed onset, muscle-ischemic symptoms dominant over CNS symptoms. Population-level response rate: unknown — no clinical trial data for MDC 002 in ME/CFS exists as of 2026 (Rücker 2026).
Certainty: 0.30. No study has simultaneously measured intracellular taurine and sodium accumulation in ME/CFS patients. Rationale is mechanistic extrapolation.
The AIMM cascade describes a deterministic sequence, but patients with similar degrees of hypoperfusion show substantially different PEM severity. The existing model contains no variable to explain this heterogeneity. Many factors could contribute (fitness level, mitochondrial reserve, autoantibody burden, autonomic tone, sleep quality, genetic variation in ion channel isoforms). Intracellular taurine status is one candidate variable: taurine acts as a two-node ionic buffer at the Na+/K+-ATPase support point (upstream ) and at calcium buffering (downstream ), effectively raising the sodium threshold at which NCX reversal occurs and the calcium threshold at which mitochondrial damage begins. Patients with higher intracellular taurine would have a larger ionic safety margin before PEM cascade onset.
Falsifiable prediction: Intracellular taurine concentration (muscle biopsy or RBC lysate proxy) inversely correlates with post-exercise sodium accumulation measured by the Petter et al. sodium MRI protocol in ME/CFS patients. A direct trial: taurine supplementation (2 g/day, 8 weeks) reduces the magnitude of intracellular sodium rise in patients with documented sodium overload.
See Section Amino Acids in Chapter Supplements and Nutraceuticals for supplement protocol.
Cardiac glycosides (digoxin, ouabain) inhibit Na+/K+-ATPase at pharmacological concentrations. However, endogenous ouabain — a steroid hormone produced by the adrenal cortex at picomolar-nanomolar concentrations — activates Na+/K+-ATPase through a distinct signaling pathway (Src kinase phosphorylation of the alpha subunit) rather than inhibiting transport. Endogenous ouabain thereby fine-tunes pump activity under physiological conditions.
Research question: If ME/CFS involves impaired Na+/K+-ATPase function (the AIMM hypothesis, Section WASF3–DRP1 Convergence: Two Routes to the Same Mitochondrial Failure), one underexplored question is whether endogenous ouabain levels are depleted in ME/CFS patients. Reduced adrenal output of this regulatory hormone could remove an activating signal from the pump, contributing to the pump failure even before the downstream ionic cascade.
Proposed measurement: Serum endogenous ouabain is measurable by radioimmunoassay. A case-control study comparing ME/CFS patients to healthy controls and patients with other fatigue conditions would be low-cost and potentially informative.
Important distinction from therapeutic use: This is a basic science question about endogenous signaling, not a rationale for cardiac glycoside therapy. Pharmacological cardiac glycosides at therapeutic doses inhibit rather than activate the pump, and have a narrow toxic window. Therapeutic cardiac glycoside use in ME/CFS would have a highly unfavorable risk-benefit ratio and is not under consideration.
2 Thyroid Hormone Regulation of Mitochondrial Function
The mechanisms of mitochondrial damage described above—oxidative stress, calcium overload, impaired mitophagy—do not operate in isolation. Thyroid hormones, particularly triiodothyronine (T3), regulate mitochondrial biogenesis, respiratory chain assembly, and quality control through well-characterized pathways in general endocrinology (Singh and Yen 2022) (Liao et al. 2024). Whether disruption of thyroid hormone signaling contributes to mitochondrial dysfunction in ME/CFS specifically has not been directly tested. Comparable mechanistic arguments could be constructed for other hormones with broad mitochondrial regulatory roles (cortisol, insulin, IGF-1), so the existence of a mechanistic overlap is necessary but not sufficient to prioritise this axis. The case for considering thyroid hormones here rests on the documented Low T3 Syndrome in ~16% of ME/CFS patients (Ruiz-Núñez et al. 2018) and the selenoprotein P autoantibody finding (Sun et al. 2023) (Chapter Endocrine and Metabolic Dysfunction, Section Thyroid Function), which provide ME/CFS-specific evidence—albeit from single unreplicated studies—for disrupted thyroid hormone availability.
T3 regulates mitochondrial function through two distinct pathways operating on different timescales (Singh and Yen 2022) (Liao et al. 2024). (Note: the relative quantitative importance of T3 versus other mitochondrial regulators—insulin signaling, AMPK, mTOR, glucocorticoids, PPAR ligands—varies by tissue and metabolic context. The description below presents the T3-specific pathways; it does not imply T3 is the dominant regulator in all settings.)
2.1 Nuclear/Genomic Pathway (Hours to Days)
T3 binds nuclear thyroid hormone receptors (TR\(\alpha\) 1 and TR\(\beta\) 1), which act as ligand-dependent transcription factors at thyroid response elements (TREs) in nuclear DNA. This activates a transcriptional cascade: T3 → PGC-1\(\alpha\) induction → NRF-1/GABPA (Nuclear Respiratory Factor 2, distinct from the Nrf2/NFE2L2 antioxidant pathway) coactivation → TFAM (mitochondrial transcription factor A) expression → mtDNA replication and transcription. The net result is increased mitochondrial mass, mtDNA copy number, and respiratory capacity over 1–several days. T3 also coordinates fission, mitophagy, and biogenesis through a pathway proposed to involve ERR\(\alpha\)-dependent ULK1 and DRP1 expression (Singh et al. 2017): in this proposed model, T3-induced DRP1-mediated fission physically separates damaged mitochondrial segments, enabling their PINK1/Parkin-dependent mitophagic clearance, while PGC-1\(\alpha\) simultaneously drives biogenesis of replacement organelles (demonstrated in specific cell types in vitro; generalisability to skeletal muscle and neurons is assumed but not confirmed). This quality-control cycle, if operative, would ensure that the mitochondrial population remains functional—a process compromised when tissue T3 is low.
2.2 Direct Mitochondrial Pathway (Minutes to Hours)
The full-length TR\(\alpha\) 1 mRNA also encodes two truncated proteins that are imported directly into mitochondria (Wrutniak-Cabello, Casas, and Cabello 2018). The p43 isoform (~43 kDa) localizes to the mitochondrial matrix, binds T3, and evidence from in vitro transactivation assays suggests it functions as a T3-dependent transcription factor of the mitochondrial genome—binding putative TREs in the mitochondrial D-loop region to promote synthesis of the 13 mitochondrial-encoded OXPHOS subunits. This dual system (nuclear + mitochondrial) ensures coordinated expression of both nuclear-encoded and mtDNA-encoded respiratory chain components; loss of either pathway produces stoichiometric imbalance and assembly defects.
2.3 Supercomplex Assembly and Cardiolipin
T3 promotes the assembly of individual respiratory complexes (I, III, IV) into supercomplexes (respirasomes), which channel electrons more efficiently and limit ROS generation (Singh and Yen 2022). Supercomplex stability depends on cardiolipin, the signature phospholipid of the inner mitochondrial membrane: T3 rapidly increases cardiolipin synthase activity, and cardiolipin acts as molecular “glue” bridging Complexes III and IV (multiple cardiolipin molecules per interface in cryo-EM structures, with variable occupancy across species). Hypothyroidism causes reduced cardiolipin content and impaired supercomplex formation—a phenotype that overlaps with the supercomplex disruption produced by WASF3 overexpression, though via distinct mechanisms (ER Stress–WASF3–Mitochondrial Dysfunction Pathway: Druggable Mechanism below). T3 deficiency and WASF3 elevation could in principle disrupt supercomplexes through complementary mechanisms (reduced assembly signals vs. active disassembly). Whether these two mechanisms co-occur in individual ME/CFS patients has not been tested—no study has measured both WASF3 levels and tissue T3 in the same cohort (Liao et al. 2024).
2.4 3,5-Diiodothyronine (T2): Rapid Mitochondrial Effects
3,5-Diiodo-L-thyronine (3,5-T2), a thyroid hormone metabolite previously considered inactive, has rapid non-genomic effects on mitochondria that are independent of protein synthesis and evident within one hour (Lombardi et al. 2015). In vitro evidence suggests 3,5-T2 interacts with Complex IV (cytochrome \(c\) oxidase), modulating the allosteric ATP-inhibitory conformation—effectively reducing the brake on terminal electron transfer (the precise binding subunit remains to be confirmed by structural studies). 3,5-T2 also stimulates fatty acid oxidation (+80–104% increase with palmitoyl substrates) via SIRT1 activation of AMPK, which phosphorylates and inhibits ACC, reducing malonyl-CoA production and thereby relieving CPT1-mediated inhibition of mitochondrial fatty acid import. T2 reduces H2O2 production while increasing respiration rate, suggesting it shifts mitochondria toward efficient coupled respiration. Whether T2 levels are altered in ME/CFS has not been investigated.
2.5 Relevance to ME/CFS: The Thyroid–Mitochondrial Convergence
Falsifiability: weakly — Falsified if (a) intramuscular T3 concentrations in ME/CFS patients with serum Low T3 are normal, or (b) T3 supplementation in Low T3 ME/CFS patients fails to improve the primary endpoint of maximal coupled respiration in muscle biopsy respirometry at 12 weeks
Certainty: 0.45. In the ~16% of ME/CFS patients with documented Low T3 Syndrome (Section Thyroid Function in Chapter Endocrine and Metabolic Dysfunction), reduced tissue T3 availability may amplify several of the mitochondrial damage mechanisms described in this section through a convergent cascade. Note that this hypothesis applies specifically to the Low T3 subgroup and does not claim to explain mitochondrial dysfunction in ME/CFS patients with normal thyroid profiles:
- Reduced PGC-1\(\alpha\) activation: Impaired mitochondrial biogenesis—fewer new mitochondria to replace damaged ones.
- Reduced cardiolipin synthesis: Destabilized respiratory supercomplexes—increased electron leak and ROS generation.
- Impaired mitophagy coordination (if the proposed ERR\(\alpha\)/ULK1/DRP1 pathway operates in relevant tissues): Reduced fission-mitophagy-biogenesis cycle—damaged mitochondria accumulate rather than being cleared (Singh et al. 2017). This step depends on a pathway demonstrated in vitro but not confirmed in human skeletal muscle or neurons.
- Potential supercomplex disruption overlap with WASF3: Low T3 reduces assembly signals while WASF3 actively disrupts assembled supercomplexes—whether these co-occur in individual patients has not been tested (Wang et al. 2023).
- Reduced p43-mediated mtDNA transcription: Insufficient production of the 13 mtDNA-encoded OXPHOS subunits, creating stoichiometric imbalance with nuclear-encoded subunits (Wrutniak-Cabello, Casas, and Cabello 2018).
A hypothesized self-reinforcing cycle could operate as follows: low tissue T3 → impaired biogenesis and quality control → accumulation of damaged, ROS-producing mitochondria. The proposed closing link—ROS-driven oxidative inactivation of deiodinase selenocysteine residues, further reducing T4-to-T3 conversion—is the weakest step in the cycle: while sustained oxidative stress can irreversibly oxidize selenocysteine to seleninic acid, this requires severe and sustained ROS levels beyond what has been directly demonstrated in ME/CFS tissues. This closing link should be treated as an open question rather than an established feedback mechanism. If it does not operate, the cycle is open (T3 deficit worsens mitochondrial function, but mitochondrial dysfunction does not necessarily worsen T3 availability through this route).
Selenoprotein P autoantibodies, documented in 9.6–15.6% of ME/CFS patients (Sun et al. 2023), represent a separate mechanism that could impair deiodinase function by reducing selenium delivery (Section Thyroid Function in Chapter Endocrine and Metabolic Dysfunction). However, this is a distinct mechanistic branch (autoimmune selenium transport impairment), not a substitute for the ROS-deiodinase closing link: it does not demonstrate that mitochondrial dysfunction causes worsened T3 availability, which is what a true self-reinforcing cycle requires. Without evidence for either closing link, the most conservative interpretation is a one-directional pathway: low T3 may worsen mitochondrial function, but whether mitochondrial dysfunction reciprocally worsens T3 availability remains an open question.
Testable predictions:
- (a): ME/CFS patients with documented Low T3 Syndrome should show lower supercomplex content (measured by blue native PAGE of muscle biopsy mitochondria) than ME/CFS patients with normal thyroid hormone profiles.
- (b): Intramuscular T3 concentrations (measured by LC-MS/MS in biopsy) should be disproportionately reduced relative to serum FT3 in patients with selenoprotein P autoantibodies.
- (c): T3 supplementation in Low T3 ME/CFS patients should increase mtDNA copy number and improve respirometric parameters (maximal coupled respiration, spare respiratory capacity) measured in PBMCs or muscle biopsy at 8–12 weeks.
Research implication: This hypothesis predicts that future clinical trials of mitochondrial cofactor supplementation (CoQ10, NAD+ precursors, carnitine) should stratify by thyroid status, as patients in the Low T3 subgroup might respond differently. This is a testable prediction, not a clinical recommendation—no evidence currently shows that cofactor supplementation fails due to T3 deficiency, and well-tolerated supplements should not be withheld pending thyroid investigation. The alternative hypothesis—that Low T3 is a protective adaptation to energy deficiency (Section Thyroid Function in Chapter Endocrine and Metabolic Dysfunction)—would predict the opposite: that correcting T3 without addressing the underlying energy deficit could worsen outcomes by raising metabolic demand beyond supply.
No study has directly measured T3 concentrations in ME/CFS skeletal muscle or other target tissues. The hypothesis that tissue-level T3 is reduced rests on indirect evidence: serum Low T3 pattern (Ruiz-Núñez et al. 2018), reduced deiodinase activity indices (SPINA-GD) (Sun et al. 2023), and the general finding that serum T3 underestimates tissue deficits when deiodinase function is impaired. Direct tissue measurement using LC-MS/MS in muscle biopsy is technically feasible but has not been performed in ME/CFS.
3 IgG Immune Complex–Mediated Mitochondrial Disruption
While the mechanisms above describe cell-intrinsic pathways of mitochondrial damage, recent evidence demonstrates that circulating immune factors can directly injure mitochondria in vascular endothelial cells. Liu et al. (2026) (Liu et al. 2026) isolated IgG immune complexes from post-infectious ME/CFS patients (n=39–40, including 15–16 with post-COVID ME/CFS) and applied them to human umbilical vein endothelial cells (HUVECs), revealing a distinct pattern of mitochondrial injury.
Patient-derived IgG induced mitochondrial fragmentation—a shift from elongated, networked mitochondria toward small, punctate organelles—detectable by confocal microscopy. Notably, this fragmentation did not result in bioenergetic collapse: Seahorse extracellular flux analysis showed that total ATP generation was maintained, with increased spare respiratory capacity and glycolytic compensation. This pattern suggests a stress adaptation response rather than outright energy failure, consistent with the clinical observation that ME/CFS patients maintain basal cellular function but fail under metabolic demand (Consequences of Energy Deficits).
Liu et al. (2026) (Liu et al. 2026) demonstrated that IgG immune complexes purified from ME/CFS patient sera are sufficient to induce mitochondrial fragmentation and inflammatory cytokine secretion (IL-1\(\beta\)) when applied to healthy endothelial cells. This “transfer experiment” establishes that a circulating humoral factor—not cell-intrinsic defects—can drive the mitochondrial structural abnormalities observed in ME/CFS. Mass spectrometry proteomics revealed disease-specific signatures in the IgG complexes: classic ME/CFS IgG was enriched in extracellular matrix reorganization pathways, while post-COVID ME/CFS IgG was enriched in hemostasis and blood clot formation pathways.
The mitochondrial fragmentation effect was predominantly observed in female patients; male-specific mechanisms remain unexplored. The HUVEC model relies heavily on glycolysis, which may mask oxidative phosphorylation effects that would manifest in more OXPHOS-dependent tissues (skeletal muscle, neurons). The IgG purification method did not effectively capture pentameric IgM, which may carry additional pathogenic activity. Not all ME/CFS patients’ IgG induced fragmentation, consistent with disease heterogeneity. Independent replication is pending.
Several features distinguish this finding from the WASF3 pathway described below. While WASF3 acts through ER stress to disrupt Complex IV assembly (a cell-intrinsic mechanism), IgG-mediated fragmentation represents an extrinsic, immune-driven pathway that alters mitochondrial morphology without targeting specific respiratory chain complexes. The two mechanisms are not mutually exclusive: IgG-induced mitochondrial stress could trigger ER stress, which in turn upregulates WASF3, creating a convergent pathway toward mitochondrial dysfunction. This immune–metabolic bridge connects to the autoantibody and immune complex evidence in Immune System Dysfunction (Autoimmunity in ME/CFS) and to the endothelial dysfunction evidence in Cardiovascular Dysfunction (Vascular Dysfunction).
4 WASF3 and ER Stress: A Specific Molecular Mechanism
A 2023 study by Wang et al., using muscle biopsies from the NIH intramural ME/CFS cohort, identified a specific molecular pathway linking cellular stress to mitochondrial dysfunction (Wang et al. 2023).
A 2023 study by Wang et al. (Wang et al. 2023), using muscle biopsies from the NIH intramural ME/CFS cohort, identified a specific molecular pathway linking cellular stress to mitochondrial dysfunction. WASF3 (Wiskott-Aldrich syndrome protein family member 3) was significantly elevated in ME/CFS patient muscle biopsies compared to controls. This protein, when overexpressed, localizes to mitochondria and disrupts respiratory chain function.
The study revealed a mechanistic chain: endoplasmic reticulum (ER) stress activation drives increased WASF3 expression, which then translocates to mitochondria where it interferes with respiratory chain supercomplex assembly, particularly affecting Complex IV (cytochrome c oxidase), resulting in decreased oxygen consumption and reduced exercise endurance. Critically, pharmacologic inhibition of ER stress in patient-derived cells improved mitochondrial function, suggesting this pathway represents a potentially druggable target. ER stress modulators or WASF3 inhibitors could restore normal mitochondrial respiration.
The WASF3 mechanism provides a molecular explanation for several ME/CFS features: viral infection can trigger ER stress through viral protein accumulation (explaining post-infectious onset), once established ER stress can become self-perpetuating (explaining chronic persistence), and Complex IV impairment directly limits oxidative capacity (explaining exercise intolerance and reduced VO2peak observed in CPET studies). Kawano et al. (2023) additionally demonstrated that ER proteostasis dysfunction in peripheral tissues generates systemic signals that regulate sleep via the unfolded protein response, providing a direct mechanistic bridge from ER stress to the unrefreshing sleep phenotype of ME/CFS (Kawano et al. 2023). This finding bridges the gap between cellular stress responses and the clinical manifestation of exercise intolerance, providing mechanistic support for the energy deficit model of ME/CFS.
Single study (Wang et al. 2023) from the NIH intramural ME/CFS cohort. While the mechanism was validated in cell culture (pharmacologic ER stress inhibition rescued mitochondrial function), no independent cohort has replicated the WASF3 elevation finding in ME/CFS muscle biopsies. The “druggable target” claim remains preclinical. Independent replication in patient tissue is required before therapeutic development.
A 2025 muscle biopsy study in long COVID and ME/CFS patients confirmed elevated WASF3 and ER stress markers with decreased Complex IV subunits, and critically demonstrated that these abnormalities differ from bed rest-induced deconditioning (2025b) (Appendix Ongoing and Planned ME/CFS Research Studies, Section Exercise Physiology and Muscle Biology). A multi-modal study in Cell Reports Medicine further showed reduced ATP/ADP ratios in immune cells, linking energy deficits to immune dysfunction (2025a) (Section Biomarker Discovery and Diagnostics).
5 ISR Context-Dependence: Activation vs. Suppression
The PERK/WASF3 data (Wang et al. 2023) establishes ISR activation in ME/CFS muscle, but evidence from multiple model systems cautions against treating ISR suppression as straightforwardly beneficial. The relationship between ISR activity and cellular outcomes is dose- and context-dependent (Costa-Mattioli and Walter 2020) (Altintas, Wek, and Wek 2024).
Protective role in acute mitochondrial stress: Baron et al. demonstrated that pharmacologic activation of ISR kinases (HRI or GCN2) promotes mitochondrial elongation and prevents DRP1-mediated fragmentation . In this context, ISR activation is a protective response that maintains mitochondrial architecture; the ISR inhibitor ISRIB blocked these protective effects . The eIF2α–ATF4 axis is also required for the transcriptional program that maintains mitochondrial dynamics and mtDNA replication during ER stress: cells lacking eIF2α phosphorylation show dysregulated mitochondrial morphology and impaired bioenergetics (Le et al. 2025).
Detrimental role under chronic activation: Conversely, genetic suppression of the GCN2–ATF4 pathway extended lifespan in Drosophila melanogaster, while overexpression shortened it . This finding — currently a preprint, not yet peer-reviewed, and directly contradicting prior yeast and C. elegans results — suggests that in more complex organisms, chronic ATF4 activity suppresses proteostasis and DNA repair capacity and is net-harmful.
Certainty: 0.35. A unifying interpretation: ISR activation in ME/CFS may be initially adaptive (protecting mitochondria from acute exertion-induced damage, limiting viral spread via translational arrest) but becomes maladaptive when sustained. Chronic eIF2α phosphorylation suppresses global anabolic synthesis, impairs mitochondrial biogenesis, and — per the Götz preprint — may reduce cellular longevity through ATF4-driven transcriptional reprogramming that trades repair capacity for stress tolerance.
Under this model, the therapeutic target is not simple ISR activation or suppression but ISR normalization: restoring appropriate pulsatile ISR responses to genuine stress signals, while preventing tonic baseline elevation. ISRIB and eIF2B activators (Costa-Mattioli and Walter 2020) would be appropriate only if tonic ISR exceeds the beneficial threshold; HRI kinase agonists would be appropriate only where mitochondrial fragmentation reflects insufficient ISR response.
Testable prediction: ME/CFS muscle will show elevated phospho-eIF2α at baseline alongside a blunted delta-ISR response to an acute stressor (tonic saturation preventing further induction). ISRIB treatment will worsen mitochondrial fragmentation markers (DRP1 phosphorylation, mitochondrial aspect ratio) in ME/CFS patient cells despite reducing phospho-eIF2α.
Limitation: The Götz lifespan data are Drosophila-only, unreviewed, and not replicated in mammals. No study has measured ISR inducibility vs. baseline level in ME/CFS patients. The tonic saturation model is mechanistic inference, not direct evidence.
Certainty: 0.45. Post-exertional malaise may represent a two-phase ISR cycle rather than a single failure state (Costa-Mattioli and Walter 2020) (Le et al. 2025) . Phase 1 (0–24 h post-exertion): acute eIF2α phosphorylation — adaptive, protective mitochondrial elongation (Baron/Wiseman mechanism ), translational pause. Symptom correlate: immediate fatigue. Phase 2 (24–72 h): ATF4-driven transcriptional reprogramming — suppresses OXPHOS subunit synthesis, induces amino acid stress genes, activates CHOP (Le et al. 2025). When chronic, this phase becomes net-harmful . Symptom correlate: delayed crash, cognitive symptoms, PEM peak. Phase 3 (recovery): GADD34/PP1-mediated eIF2α dephosphorylation; if impaired, no full recovery and symptoms persist (Costa-Mattioli and Walter 2020).
The characteristic 24–48 h delay between exertion and PEM peak matches ISR temporal kinetics precisely. The PERK elevation found in ME/CFS muscle (Wang et al. 2023) is consistent with this hypothesis: a constitutively elevated PERK baseline would shift the Phase 1/Phase 2 boundary earlier and make Phase 2 persist longer.
Testable prediction: Time-course muscle biopsy using a standardized CPET protocol (pre / +6h / +24h / +48h / +7d post-exertion) will show distinct temporal waves: phospho-eIF2α peaking early, ATF4 target gene expression (ASNS, FGF21 mRNA, GDF15 mRNA) peaking at 24–48 h. Healthy controls will show resolution by 72 h; ME/CFS patients will show persistence. If ISR markers are flat or non-temporal across timepoints → hypothesis falsified.
Limitation: No time-resolved ISR biopsy study in ME/CFS exists. GADD34 impairment is a mechanistic inference not yet tested. The two-phase model borrows temporal kinetics from model systems (cell culture, animal) that may not translate quantitatively to human skeletal muscle.
Certainty: 0.40. Persistent low-grade ATF4 activity creates a “metabolic ceiling” that PEM cannot exceed (Costa-Mattioli and Walter 2020). ATF4, the master ISR transcription factor induced downstream of all four eIF2α kinases, represses mitochondrial OXPHOS subunit translation and activates amino acid metabolism genes (aminoacyl-tRNA synthetases, one-carbon/serine pathway flux), diverting resources away from energy production toward stress tolerance. In the Götz Drosophila model, this chronic ATF4 activity reduced lifespan and suppressed proteostasis and DNA repair ; in the Le 2025 cell model, the acute eIF2α–ATF4 axis is required for mitochondrial maintenance, but chronic activation becomes maladaptive (Le et al. 2025).
In ME/CFS, if the ATF4 axis is tonically elevated (via chronic PERK activation from WASF3/ER stress (Wang et al. 2023)), then the maximum achievable OXPHOS output is structurally constrained at a lower ceiling than in healthy individuals — not because ATP synthesis machinery is destroyed, but because its transcription is chronically suppressed by the ISR reprogramming response.
Testable prediction: ATF4 ChIP-seq in ME/CFS skeletal muscle will show enrichment at mitochondrial gene promoters (suppressive occupancy) and amino acid metabolism gene promoters (activating occupancy). Serum ATF4-target metabolites — GDF15, FGF21, asparagine, serine, and glycine ratios — will be elevated relative to matched controls. If no ATF4 target signature is detectable in ME/CFS muscle → hypothesis falsified.
Limitation: Götz data are Drosophila-only and not replicated in mammals. No direct ATF4 ChIP-seq data exists in ME/CFS muscle. The ceiling model assumes chronic activation; acute protective activation is beneficial and should not be suppressed (see Chronic ISR Activation in ME/CFS: Adaptive Initiation, Maladaptive Persistence).
Certainty: 0.30. Wang’s WASF3 mechanism (ER stress → WASF3 → supercomplex disruption (Wang et al. 2023)) and Prusty’s HHV-6 miR-aU14 mechanism (viral miRNA → DRP1 activation → mitochondrial fragmentation (Hennig et al. 2022)) converge on the same downstream outcome — mitochondrial dysfunction and exercise intolerance — via parallel but potentially additive routes. WASF3 impairs respiratory supercomplex assembly; DRP1 fragments the organelle before assembly can occur. Whether WASF3 also promotes DRP1 recruitment to mitochondria is currently unstudied.
If these mechanisms are additive, patients with both HHV-6 reactivation (miR-aU14 active) and elevated WASF3 would have the most severe mitochondrial dysfunction and exercise intolerance — a prediction consistent with the dose-response pattern in clinical ME/CFS severity. ISR kinase activation protects against DRP1-mediated fragmentation but not against WASF3-mediated supercomplex disruption, predicting partial rather than complete rescue by HRI agonists.
Testable prediction: WASF3 knockdown in HHV-6 miR-aU14-expressing cells will partially rescue mitochondrial morphology but not completely. DRP1 inhibitor (Mdivi-1 or Drpitor1a) will rescue the miR-aU14 phenotype but not the WASF3 phenotype. If these are independent, combined inhibition will be additive; if WASF3 acts downstream of DRP1, DRP1 inhibition will rescue both.
Limitation: The convergence is inferred from two separate model systems (Wang: human muscle biopsies/fibroblasts; Hennig: viral cell models). No study has simultaneously measured WASF3 expression and miR-aU14 activity in the same ME/CFS patient samples.
6 The Sodium-Calcium Overload Cascade
Wirth and Scheibenbogen integrated emerging evidence into a model of ion homeostasis failure in ME/CFS. The cascade begins with hypoperfusion (Section Step 1: Substrate Delivery - Glucose, Fatty Acid, and Oxygen Uptake), which forces cells into anaerobic metabolism. Anaerobic metabolism generates protons as a byproduct. Accumulating protons increase the activity of the sodium-hydrogen exchanger (NHE1), which extrudes protons by importing sodium. Under normal aerobic conditions, the Na+/K+-ATPase can clear this sodium, but under hypoperfusion and ATP limitation, this pump becomes saturated and dysfunctional.
When the Na+/K+-ATPase fails to maintain the inward sodium gradient, the plasma membrane sodium-calcium exchanger NCX1 (SLC8A1)—which operates electrogenically in a 3 Na+:1 Ca2+ exchange—reverses direction. In forward mode NCX1 imports three sodium ions to export one calcium ion; in reverse mode (driven by elevated intracellular Na+) it imports one calcium ion per cycle. The thermodynamic reversal point is set by the NCX reversal potential \(E_\text{NCX} = 3 E_\text{Na} - 2 E_\text{Ca}\), where \(E_\text{Na}\) and \(E_\text{Ca}\) are the Nernst potentials for Na+ and Ca2+ respectively. As intracellular Na+ rises, \(E_\text{Na}\) shifts positive, lowering \(E_\text{NCX}\) below the resting membrane potential and driving sustained reverse-mode calcium import.
Critically, the mitochondrial sodium-calcium exchanger NCLX (SLC8B1)—the primary route of calcium efflux from the mitochondrial matrix—is simultaneously impaired: NCLX imports Na+ to export Ca2+, so cytoplasmic sodium overload reduces its driving force. Sodium accumulation therefore traps calcium inside mitochondria via two independent routes: influx through reversed NCX1 and blocked efflux through NCLX. The combined result is mitochondrial calcium overload, direct damage to the electron transport chain, amplified ROS production, and further ATP depletion—reinforcing the original sodium overload.
Petter et al. provided the first direct in vivo quantification using 23Na-MRI in ME/CFS patients (\(n = 6\) per group). Baseline intracellular sodium was elevated across all five lower-leg muscle compartments (12.20 mM vs 9.38 mM in anterior extensors; \(p = 0.0034\)). Post-exercise sodium accumulation was greater in ME/CFS, and intracellular sodium correlated inversely with hand-grip strength (\(p = 0.0319\))—a quantitative link between the ionic signature and functional impairment. Wirth et al. extended these findings with electron microscopy showing subsarcolemmal mitochondrial damage preferentially localized at sites of calcium influx, consistent with NCLX-mediated calcium trapping.
Scheibenbogen and Wirth synthesized accumulated histological, MRI, and proteomic data into the concept of acquired ischemic mitochondrial myopathy (AIMM): a disease phenotype in which post-infectious vascular dysfunction produces chronic muscle ischemia, driving the NHE1 → Na+ overload → NCX1 reversal → NCLX block → calcium overload → mitochondrial damage cycle as a self-reinforcing acquired pathology, distinct from primary genetic mitochondrial diseases. Proteomics confirmed reduced expression of Na+/K+-ATPase subunits (weakened sodium clearance capacity) and upregulated ENaC expression (sodium-sensing retention), indicating the dysfunction involves sustained pathological remodeling at the protein level. The AIMM framing has a direct therapeutic implication: an acquired ionic myopathy is potentially reversible through pharmacological correction of the sodium/calcium overload, without requiring genetic intervention (see Section Sigma-1 Receptor Mechanisms and Fluvoxamine Therapy in Chapter Emerging and Investigational Therapies).
7 TRPM3 Ion Channel Dysfunction
Cabanas et al. (Cabanas et al. 2024) studied TRPM3 calcium channels in natural killer (NK) cells from ME/CFS patients and found reduced calcium influx amplitude and prolonged half-time (slower kinetics). TRPM3 is critical for NK cell calcium signaling and cytotoxic function. Importantly, low-dose naltrexone (LDN) restored TRPM3-dependent calcium influx in patient NK cells in vitro, suggesting a reversible pharmacological mechanism. Sasso et al. extended these findings with large-scale validation confirming the TRPM3 dysfunction across broader patient populations.
8 WASF3 and ER Stress-Induced Metabolic Switching
Wang et al. (Wang et al. 2023) (cross-referenced as WASF3 studies in Chapter Mechanistic and Experimental Studies) identified endoplasmic reticulum (ER) stress upregulation of WASF3 (Wiskott-Aldrich syndrome protein family member 3). WASF3 simultaneously disrupts respiratory supercomplex assembly (impairing OXPHOS efficiency) and promotes actin polymerization, driving a forced switch toward glycolysis. Muscle biopsies from ME/CFS patients showed elevated WASF3 expression, confirming ER stress-mediated metabolic reprogramming.
This represents a cell-autonomous mechanism: ER stress—triggered by calcium overload, oxidative stress, or viral persistence—activates a program that simultaneously reduces OXPHOS capacity while increasing glycolytic flux. Even if mitochondria are structurally intact, WASF3-mediated disruption of supercomplexes reduces their efficiency.
9 Distinction: Production vs. Utilization Defects
These mechanisms reveal a critical distinction: ATP production defects (failing mitochondria, substrate delivery) are different from ATP utilization defects (ion pump failure, calcium overload, forced metabolic switching). Both limit cellular energy availability, but they require different therapeutic targets. A patient with sodium-calcium overload may have normal mitochondrial capacity but cannot function because ion homeostasis is broken. A patient with WASF3-driven supercomplex disruption may have sufficient ATP but inefficient energy use due to forced glycolysis.
10 Immune-Metabolic Crosstalk Maintaining the Energy Crisis
Immune activation is not independent of metabolic dysfunction—instead, immune-mediated pathways actively maintain and amplify the energy crisis. This creates a feedback loop where immune activation perpetuates energy failure.
10.1 Tryptophan-Kynurenine Metabolism and NAD+ Depletion
The tryptophan-kynurenine pathway is one of the primary immune-activated routes of tryptophan catabolism. Elevated kynurenine production is associated with chronic immune activation (elevated IFN-\(\gamma\), TNF-\(\alpha\)). However, the balance of kynurenine metabolites matters: normal kynurenine metabolism feeds into NAD+ synthesis, supporting mitochondrial energy production; imbalanced metabolism produces neurotoxic metabolites while depleting NAD+.
A recent metabolomics study (Abujrais, Vallianatou, and Bergquist 2024) (published in ACS Chemical Neuroscience) profiled tryptophan metabolism in ME/CFS plasma and found higher 3-hydroxykynurenine (a neurotoxic branch product), lower kynurenic acid (neuroprotective, NAD+-producing), and lower quinolinic acid (a neurotoxic NMDA agonist that also feeds NAD+ synthesis via QPRT). The net effect: immune-mediated tryptophan catabolism is diverted away from NAD+ synthesis and toward neurotoxic branches. This directly links immune activation to NAD+ depletion and impaired mitochondrial function.
10.2 T-Cell Exhaustion with Metabolic Reprogramming
Iu et al. (Iu et al. 2024) (published in PNAS) profiled CD8+ T cell epigenetics and metabolism in ME/CFS, finding that T cells are epigenetically primed toward an exhausted phenotype (high PD-1, TIM-3, LAG-3) while simultaneously showing altered metabolic reprogramming. Post-exercise, this metabolic dysregulation worsened. This suggests T cells cannot sustain normal metabolic flexibility in response to immune demands, contributing to both the dysfunctional immune response and persistent metabolic strain.
10.3 Exaggerated Innate Immune Response with Metabolic Consequences
Che, Hornig, and Lipkin (published in npj Metabolic Health and Disease) documented an exaggerated innate immune response to standard challenges in ME/CFS. Their metabolomic data showed that immune activation is associated with impaired citric acid cycle (TCA cycle) flux and reduced beta-oxidation capacity. Mechanistically, IFN-gamma (elevated in their cohort) accelerates tryptophan degradation via indoleamine 2,3-dioxygenase (IDO), directly linking innate immune state to NAD+ depletion and energy failure.
10.4 Oxidative Stress in Immune Cells
Shankar et al. (Shankar et al. 2025) (published in PNAS) measured reactive oxygen species (ROS) in circulating lymphocytes from ME/CFS and Long COVID patients. They found elevated ROS in memory T cells, with striking sex differences: females showed higher ROS production and T-cell hyperproliferation; males showed evidence of mitochondrial lipid oxidative damage. Critically, metformin treatment attenuated T-cell hyperproliferation in vitro, suggesting ROS-driven immune dysregulation may be pharmacologically reversible.
10.5 Mitochondrial Fragmentation in Immune Cells: The DRP1 Connection
Schreiner et al. (2020) provided mechanistic evidence that HHV-6 reactivation triggers DRP1-mediated mitochondrial fragmentation in ME/CFS PBMCs (Schreiner et al. 2020), establishing that the same fission machinery implicated in neuronal mitochondrial dysfunction operates in immune cells. Missailidis et al. (2020) demonstrated that EBV-immortalized ME/CFS lymphocytes carry an isolated Complex V (ATP synthase) defect with compensatory respiratory upregulation and proton leak (Missailidis et al. 2020). Despite normal resting ATP, these cells exhaust their reserve capacity under activation — the same demand-response failure pattern observed in skeletal muscle. Critically, T-cell subset counts are within normal range (Cliff 2019, n=251 (Cliff et al. 2019)), confirming that ME/CFS immune dysfunction is metabolic and functional, not numerical. The integrated model: post-infectious triggers (viral reactivation, ER stress) → DRP1 activation → mitochondrial fragmentation → failed metabolic reprogramming in CD8+ effector memory T cells → epigenetic exhaustion (Iu 2024 (Iu et al. 2024)) → impaired immune surveillance and viral clearance. This pathway is developed in full in Chapter Immune System Dysfunction, Hypothesis CD8+ T-Cell Mitochondrial Fragmentation Underlies Acquired Immune Exhaustion.
10.6 Immune Exhaustion: Suppression in ME/CFS, Activation in Long COVID
The largest direct immunophenotyping comparison of the two conditions (Petrov 2026, n=207 total) identified divergent immune states: Long COVID shows monocyte polarization, dendritic cell expansion, and persistent immune activation with features of exhaustion; ME/CFS shows reduced costimulatory molecule expression, impaired CCR7 trafficking, and less coordinated activation — a pattern of immune suppression, not activation-driven exhaustion (Petrov et al. 2026). This distinction is mechanistically critical: the same systemic energy failure that cripples mitochondrial function in neurons and muscle also suppresses immune cell activation capacity. The metabolic cost of immune activation cannot be met. Eaton-Fitch et al. (2024) confirmed this divergence at the gene expression level: ME/CFS PBMCs showed downregulated interferon signaling and immunoglobulin genes (suppression), while Long COVID showed dysregulated antigen presentation and cytokine signaling (activation) (Eaton-Fitch et al. 2024).
Lee et al. (2025), using the UK ME/CFS Biobank (n=96), found that severe ME/CFS is distinguished from mild/moderate by increased cytotoxic effector molecule expression and enhanced early immunosenescence (CD28−) markers (Lee et al. 2025). This suggests that the immune suppression in ME/CFS is not static — it progresses with disease severity toward a senescent exhaustion state, consistent with the accelerated immune aging documented in Section Immunosenescence and Accelerated Immune Aging.
10.7 Multi-Omics Integration: The Full Picture
The Heng 2025 multi-omics study (Heng et al. 2025) integrated cellular ATP profiling with plasma proteomics from 61 matched pairs, revealing coordinated abnormalities: elevated AMP and ADP with a reduced ATP/ADP ratio (indicating cellular energy stress), altered immune cell subsets skewed toward less mature effector populations, and elevated vascular dysfunction markers (VWF, fibronectin, thrombospondin-1). A 7-biomarker panel spanning these three domains achieved 91% diagnostic accuracy (Section Systems Biology Perspective on ME/CFS in Chapter Integrative Models and Multi-System Pathophysiology).
These findings were substantially extended by Hoel et al. (2026) (Hoel et al. 2026), who applied aptamer-based proteomics (SomaScan, 7,326 aptamers targeting 6,493 proteins) to serum from 50 ME/CFS patients and 29 healthy controls. Their analysis revealed a striking metabolic enzyme signature: key glycolytic enzymes—glyceraldehyde-3-phosphate dehydrogenase (GAPDH), fructose-bisphosphate aldolase A (ALDOA), and L-lactate dehydrogenase B chain (LDHB)—were among the most significantly reduced intracellular proteins in ME/CFS serum. Since these enzymes are normally abundant in skeletal muscle, their reduced circulating levels suggest decreased muscle protein turnover or altered cellular release patterns rather than simple enzyme deficiency. Notably, ATP synthase inhibitory factor 1 (ATP5IF1), which regulates mitochondrial ATP hydrolysis under hypoxic conditions, was also reduced, consistent with the mitochondrial stress protection deficit described in Section The Energy Chain: Ten Steps from Substrate to ATP.
Complementing the intracellular enzyme reductions, Hoel et al. found chronically elevated metabolic stress hormones: FGF-21 was significantly higher in ME/CFS patients, validated by ELISA in an extended cohort (n = 212 ME/CFS, n = 66 HC), with women showing a particularly significant elevation. GDF-15, leptin, resistin, and fatty acid-binding proteins FABP3 and FABP4 were also elevated. FGF-21 and GDF-15 are “exerkines” that normally rise transiently during intense exercise to coordinate systemic energy adaptation (Hoel et al. 2026). Their chronic elevation in ME/CFS—in the absence of intense exercise—suggests a state of persistent metabolic emergency signaling, as though the body is continuously experiencing the energy crisis of maximal exertion at rest. This pattern connects to the clinical observation that ME/CFS patients describe exhaustion disproportionate to activity level: their metabolic stress signaling reflects a genuine cellular energy crisis, not a perceptual distortion.
Together, these studies demonstrate that energy metabolism dysfunction in ME/CFS is not limited to mitochondrial abnormalities but extends to a coordinated shift in the circulating metabolic landscape: reduced intracellular metabolic enzymes, elevated stress hormones, and altered secretory patterns spanning multiple tissues. Breaking this cycle may require simultaneous intervention at multiple levels—addressing both the mitochondrial energy deficit and the chronic stress signaling that perpetuates it. This coordinated vascular-metabolic defect is further illustrated by a proposed irisin–TSP-1 axis, in which the vascular marker thrombospondin-1 antagonises the exercise-induced myokine irisin at the HSP90\(\alpha\)/αvβ5 integrin, linking endothelial activation to impaired metabolic adaptation during PEM (see TSP-1 as a Vascular–Metabolic Convergence Node, (Souma et al. 2026)).
11 The Multi-Level Vicious Cycle
Integrating findings from vascular, metabolic, and immune domains reveals a multi-level positive feedback loop where dysfunction at any level amplifies all others. This model, synthesized by Wirth, Scheibenbogen, and colleagues, explains both the severity and persistence of the energy crisis.
11.1 The Cycle in Detail
The vicious cycle operates as follows:
Vascular dysfunction (Section Step 1: Substrate Delivery - Glucose, Fatty Acid, and Oxygen Uptake): Endothelial dysfunction, RBC deformability impairment, and capillary remodeling reduce oxygen and substrate delivery to tissue.
Ischemia: Reduced oxygen availability forces cells toward anaerobic metabolism, producing lactate and protons.
Proton accumulation: Intracellular acidosis increases sodium-hydrogen exchanger (NHE1) activity, importing sodium to extrude protons.
Sodium overload: Na+/K+-ATPase is insufficient to clear accumulated sodium, particularly under ATP limitation.
NCX1 reversal + NCLX block: Elevated intracellular Na+ shifts the NCX1 reversal potential, driving reverse-mode calcium import. Simultaneously, sodium overload reduces the driving force of the mitochondrial calcium exporter NCLX (SLC8B1), trapping calcium in the mitochondrial matrix.
Calcium overload: Cytoplasmic and mitochondrial calcium accumulate via these two independent mechanisms, causing direct mitochondrial damage at subsarcolemmal sites, further impairing ATP production.
Mitochondrial dysfunction: Damaged mitochondria produce less ATP and more ROS.
ROS amplification: Elevated ROS damages endothelial cells, further impairing vascular function; damages Na+/K+-ATPase, reducing sodium clearance; and damages RBC membranes, further reducing deformability.
Return to step 1: ROS-mediated vascular damage perpetuates the original ischemia.
This is not a linear pathway with a beginning and end. Rather, it is a positive feedback loop where each step amplifies the next, and dysfunction propagates in all directions simultaneously.
11.2 Multi-Level Integration
Critically, this cycle operates at multiple biological levels simultaneously:
- Vascular level: Endothelial dysfunction → reduced perfusion
- Cellular level: Ischemia → anaerobic metabolism, ion dysregulation, mitochondrial damage
- Molecular level: ROS, calcium, sodium dysregulation → persistent vascular and mitochondrial injury
- Immune level: Immune activation accelerates tryptophan catabolism (NAD+ depletion) and oxidative stress, perpetuating energy failure
No single level can be addressed in isolation. A therapeutic intervention that improves mitochondrial function alone, without addressing vascular dysfunction or ion dysregulation, will have limited impact because ROS and calcium overload will continue to damage mitochondria. Similarly, anti-inflammatory therapy alone cannot restore energy if vascular dysfunction persists. Effective treatment likely requires simultaneous multi-level intervention.
11.3 Evidence for the Integrated Cycle
Appelman et al. (Appelman et al. 2024) (published in Nature Communications) studied muscle mitochondrial function before and after post-exertional malaise (PEM). They found that exercise triggered reductions in OXPHOS capacity and succinate dehydrogenase (SDH) activity, consistent with mitochondrial damage during PEM. Importantly, this occurred despite normal cardiopulmonary responses during exercise—the heart and lungs functioned normally, confirming that the energy crisis is peripheral (muscle) and mitochondrial, not cardiopulmonary.
Syed et al. (published in Physiology) provided a comprehensive review of mitochondrial dysfunction across ME/CFS literature, synthesizing evidence from biochemistry, imaging, genetics, and clinical studies. Their analysis supports the multi-level model: mitochondrial pathology is real and well-documented, but its severity and persistence are amplified by upstream vascular, immune, and ion dysregulation.
ME/CFS pathophysiology is fundamentally a multi-level positive feedback loop where vascular dysfunction → ischemia → ion dysregulation → mitochondrial damage → ROS → vascular amplification, perpetuated by immune-mediated NAD+ depletion and metabolic reprogramming. Unlike linear models predicting clear breakpoints for intervention, this cycle requires multi-level therapeutic targeting. Evidence comes from multiple independent research groups documenting vascular pathology (Scherbakov, Haffke, Wust, Mueller), ion dysregulation (Wirth, Scheibenbogen), mitochondrial damage (Appelman), and immune-metabolic coupling (Che, Hornig, Lipkin; Paul, Bhatt; Germain). The cycle is consistent with both symptom severity (multiple simultaneous failures) and disease persistence (mutual amplification). Scheibenbogen and Wirth formalised this as a proposed framework termed AIMM, noting that its acquired character implies potential reversibility—a claim that itself awaits direct human validation. Falsifiable predictions: (1) combination interventions targeting ≥2 cycle levels will produce greater sustained benefit than mono-target approaches in RCT comparison; (2) patients with elevated intracellular muscle sodium by 23Na-MRI will show greater response to ion-homeostasis-correcting therapies than patients with normal sodium; (3) correcting sodium overload alone will attenuate but not fully resolve the cycle. Certainty: 0.55 (mechanistic evidence for individual cycle components comes from multiple independent groups; the integrated positive feedback loop is logical inference not yet demonstrated in a single interventional study; the ion cascade sub-component rests primarily on one small pilot requiring independent replication; AIMM reversibility is an untested sub-claim).
The vicious cycle model (vascular → ischemia → ion dysregulation → mitochondrial damage → ROS → vascular amplification) integrates findings from multiple independent research groups, but no single study has demonstrated the complete loop operating in ME/CFS patients. Each link is supported by evidence from separate cohorts using different methodologies. The integration is logical inference, not empirical demonstration. Positive feedback loops are inherently difficult to distinguish from parallel independent dysfunctions that happen to co-occur. The therapeutic implication that multi-level targeting is required has not been tested against sequential single-target intervention.